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Background: Proteomic discovery of cancer biomarkers in body fluids is challenging because of their low abundance in a complex
background. Altered gene expression in tumours may not reflect protein levels in body fluids. We have tested combining gene
expression profiling of tumours with proteomic analysis of cancer cell line secretomes as a strategy to discover urinary biomarkers
for bladder cancer.
Methods: We used shotgun proteomics to identify proteins secreted by three bladder cancer cell lines. Secreted proteins with
high mRNA levels in bladder tumours relative to normal urothelium were assayed by ELISA in urine samples from 642 patients.
Results: Midkine and HAI-1 were significantly increased in bladder cancer patients, with the highest levels in invasive disease
(area under the receiver operating characteristic curve 0.89 vs non-cancer). The urinary concentration of both proteins was too
high to be explained by bladder cancer associated haematuria and most likely arises by direct tumour secretion.
Conclusions: This ‘dual-omic’ strategy identified tumour secreted proteins whose urine concentrations are increased significantly
by bladder cancer. Combined secretome-transcriptome analysis may be more useful than direct proteomic analysis of body fluids
for biomarker discovery in both bladder cancer and other tumour types.
Despite intensive efforts to discover useful biomarkers for the non-
invasive detection of cancer using increasingly powerful ‘omic’
technologies there is still a dearth of diagnostic markers available
(Anderson, 2010). If such markers do actually exist they have
evaded discovery due to their low concentration in very complex
backgrounds. The methodological difficulties such samples present,
particularly in proteomic work, should not be underestimated (Ray
et al, 2011). A recently adopted approach has been to compare
proteomic analysis of proteins secreted from cancer-specific cell
lines to changes in gene expression in cancer tissue from the same
cancer type (Chang et al, 2010, 2011; Wang et al, 2011; Yu et al,
2011). We now apply this method, for the first time, to the
discovery of urinary biomarkers for the detection of bladder
cancer.
Bladder cancer is the fifth most common cancer in Western
populations (van Rhijn et al, 2009) with over 10 000 new cases and
5000 deaths attributed to bladder cancer each year in the UK alone
(www.cancerresearchuk.org). Over 90% of these bladder cancers
are urothelial carcinomas of the bladder (UCB) (Kaufman et al,
2009). At presentation over 70% of patients with UCB have
non-muscle-invasive disease (stages Ta/T1/Tis), which is treated
primarily by endoscopic resection (Kaufman et al, 2009). Muscle-
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invasive UCB (stages T2–4) is a life-threatening disease,
which requires more radical treatment (chemotherapy and/or
cystectomy/radiotherapy). Patients with non-muscle-invasive UCB
require long-term surveillance to detect recurrent tumours with the
potential to progress to muscle-invasive disease. The mainstay of
surveillance is flexible cystoscopy combined with urine cytology
(Babjuk et al, 2011). Flexible cystoscopy is considered the gold
standard, although recent optical enhancement modalities have
shown that the sensitivity of white light cystoscopy is limited
(Cauberg et al, 2009). Cytology is very specific but has low
sensitivity for early-stage disease (Lotan and Roehrborn, 2003).
Several urine biomarker tests have been commercialised including
NMP22 (nuclear matrix protein 22), BTA TRAK/stat (based
on complement factor H) and UBC (cytokeratins 8 and 18)
(Tilki et al, 2011), but have not proven sufficiently reliable to gain
widespread acceptance.
Proteomic analyses of urine have revealed additional UCB
biomarkers such as calreticulin (Kageyama et al, 2004), Reg-1
(Orenes-Pin˜ero et al, 2007) and ADAM 28 (Yang et al, 2011);
however, many of the reported ‘biomarkers’ are serum proteins
(Irmak et al, 2005; Chen et al, 2010; Yang et al, 2011; Linde´n et al,
2012) and are therefore unlikely to be UCB specific. Urine is a
variable and difficult biospecimen for proteomic analysis, compris-
ing of plasma proteins in addition to proteins arising from the
kidneys and urothelium (Nagaraj and Mann, 2011). In addition,
haematuria is a complicating factor to a greater or lesser extent in
many UCBs (Bryan et al, 2011). An alternative source of candidate
biomarkers is proteomic analysis of the conditioned media from
cell lines or ‘secretomes’ (Volmer et al, 2005; Grønborg et al, 2006).
Selecting relevant candidates from the large number of proteins
typically identified is often based on quantitative comparisons
between cell lines. In the case of bladder cancer, Kawanishi et al
(2008) searched for markers of aggressive bladder cancer by
comparing the secretomes of an invasive cell line (T24) with a less
invasive cell line (RT112) and Makridakis et al, 2010 compared the
secretomes of the T24 cell line with a derivative cell line (T24M)
with a more aggressive phenotype. However, although this
approach aims to detect aggression specific proteins, it is not
appropriate for the detection of biomarkers for early disease.
To achieve this, a comparator is required which represents non-
cancer tissue, that is, primary cell culture or an immortalised
‘normal’ cell line (usually achieved by hTERT overexpression).
Primary cells have limited lifespans and may be less resistant
to the serum-free conditions required to harvest secreted proteins,
and while immortalised normal cells are easier to culture they have
not been widely used in comparative proteomic analyses of
secretomes.
Microarray, and more recently next generation sequencing
technologies have generated comprehensive, publically available
gene expression profiles for many cancer types. Such data may not
accurately reflect the concentrations of all proteins in cancers and
are even less likely to predict protein secretion rates. Therefore,
gene expression data per se may not predict which proteins
could be useful as biomarkers in body fluids. Proteins which are
both over expressed and detectable in cell line secretomes may be
more useful for this purpose. Recently, this approach has been
applied successfully to head and neck, lung and pancreatic cancers
(Chang et al, 2010, 2011; Wang et al, 2011; Yu et al, 2011).
We hypothesised that a combined secretome-transcriptome
strategy could reveal novel biomarkers for the detection of UCB.
Ten candidate biomarkers with elevated gene expression in UCB
and that were detected reproducibly in the secretome of multiple
UCB-derived cell lines were shortlisted. Two of these candidates,
midkine and HAI-1, were assayed in the urine of over 600 patients
and as a control we also measured a third protein that was detected
in the secretomes, but was not found to have an elevated gene
expression in UCB.
MATERIALS AND METHODS
Bladder cell line secretomes. 5637 and HB-CLS-2 cells were
purchased from CLS Cell Lines Service GmbH (Eppelheim,
Germany) and EJ28 cells were a kind gift from Elizabeth Hodgkins,
University of Birmingham. The cells were prepared in SILAC
media (Life Technologies, Paisley, UK) to enable quantitative
analysis although this was not used in this study. Cells were grown
in SILAC RPMI 1640 Flex-Media supplemented with glutamine,
glucose, 10% dialysed FCS and 12C6lysine and
12C6arginine (5637
and HB-CLS-2) or 13C6lysine and
13C6arginine (EJ28). Each cell
line was grown to 80% confluence in 4 75 cm2 flasks, washed
four times with PBS and four times with serum-free DMEM
(phenol red free) and incubated for 18 h at 37 1C (5% CO2) in
serum-free media. The conditioned media were filtered using
0.22 mm filters and concentrated using 15ml 3 kDa spin-filters.
Proteins were then reduced (50mM DTT), alkylated (100mM
iodoacetamide) and digested with trypsin overnight using the
FASP method (Wis´niewski et al, 2009). The resulting peptides were
separated into 15 fractions by mixed-mode anion exchange/
reverse-phase HPLC using a 2.1 50mm2 Acclaim Mixed-mode
WAX-1 HPLC column (Dionex, Camberley, UK) and a gradient of
0–40% B over 40min (A: 20mm ammonium formate pH 6.5, 3%
acetonitrile, B: 2mm ammonium formate pH 3.0, 80% acetoni-
trile). The fractions were dried under vacuum, dissolved in 1%
formic acid and analysed by LC-MS/MS using a 90min 0–40%
acetonitrile gradient in 0.1% formic acid (75 mm 25 cm C18
Pepmap column, Dionex) and a micrOTOF-Q II mass spectro-
meter (Bruker Daltonics, Bremen, Germany). Proteins extracted
from the corresponding cell pellets were trypsinised using the
FASP method and analysed in triplicate using a 2-h gradient on a
maXis impact mass spectrometer (Bruker Daltonics) without pre-
fractionation. For both types of experiment peptides were
identified using MASCOT 2.3 to search a custom database
containing SWISSPROT human and bovine sequences and
randomised versions thereof (bovine sequences were included as
the secretomes will inevitably contain traces of FCS). Mass
tolerances for parent and fragment ions were 20 p.p.m. and
0.05Da, respectively and the minimum peptide Mowse score was
20. Modifications considered were carbamidomethylation (fixed),
methionine oxidation (variable) and 13C6lysine and
13C6arginine
(variable, EJ28 cells only). Protein identifications were filtered
using both a 1% false discovery threshold and a requirement for
two or more peptides using Proteinscape 2.1 software.
Microarray data. We re-analysed, GSE3167 (Dyrskjøt et al, 2004)
and GSE7476 (Mengual et al, 2009), two publicly available UCB
microarray data sets, to identify mRNAs upregulated in stage Ta
UCB. Affymetrix Human Genome U133A and U133 Plus 2.0
arrays were used to generate these data. Both data sets can be
obtained from the Gene Expression Omnibus. Data set GSE7474
profiled 12 pooled samples, each containing RNA from bladder
tissue from 4 or 5 patients. There were three pools each of normal
bladder, low grade Ta UCB, high-grade T1 UCB and T2þ UCB.
Data set GSE3167 profiled bladder tissue from 60 patients
including 14 normal bladders, 15 Ta UCB, 18 Ta or T1 with CIS
and 13 T2þ UCB (the Ta UCBs with surrounding CIS were not
included in our analysis).
Patient samples. Urine samples were prospectively collected for
biomarker research between 2006 and 2009 as part of the Bladder
Cancer Prognosis Programme (BCPP, ethics approval 06/MRE04/
65) (Zeegers et al, 2009). Patients were enrolled into the study
on the basis of initial findings suggestive of primary UCB
(predominantly abnormal cystoscopy). Mid-stream urine was
collected before commencing treatment. Urine samples were
placed on ice, centrifuged at 2000 r.p.m. for 10min within 8 h of
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collection and the supernatant stored in 1ml aliquots at  80 1C.
As patient recruitment occurred before definitive histopathological
confirmation of UCB following transurethral resection, a propor-
tion of the patients were ultimately diagnosed with non-UCB
conditions and these serve as our non-cancer ‘controls’. Patient
information is summarised in Table 1.
Biomarker validation. Candidate biomarkers were measured in
urine and serum sample using commercially available ELISA
kits (DY258, DY1048 and DY1298, R&D systems, Abingdon, UK)
according to the manufacturer’s instructions. Standards and
samples were diluted in PBS containing 1% BSA and 20–40 ml of
urine or 20 ml of serum was used per assay. Samples were
randomised across multiple ELISA plates. Urinary creatinine,
albumin, total protein and haematuria were determined previously
(Bryan et al, 2011).
Data analysis. The significance of protein concentrations in
different patient groups was assessed by Mann–Whitney test.
Biomarker potential was assessed by receiver operating character-
istic (ROC) analysis. For microarray data, probe level quantile
normalisation (Bolstad et al, 2003) and RMA (robust multi-array
analysis) (Irizarry et al, 2003) were performed using the affy
package of the Bioconductor project (http://www.bioconductor.
org). Differentially expressed probe sets were identified using
limma (Smyth, 2004) using criteria of fold change 42.5 and
Po0.001. Some genes had multiple probe sets and were considered
as differentially expressed as long as one of their probe sets met
these criteria.
RESULTS
Proteomic analysis of UCB cell line secretomes. In total, 1001
human proteins were identified by two or more peptides in the
secretomes of one or more of the three cell lines (EJ28, 5637 and
HB-CLS-2). There was considerable overlap between the secre-
tomes with 480 proteins being identified in at least two out of three
secretomes and 256 detected in all three (all identifications are
listed in Supplementary Information). The secretomes were
substantially enriched for extracellular proteins compared with
the corresponding cell pellets (Figure 1).
Analysis of UCB microarray data. Data sets GSE7476 and
GSE3167 were examined to identify substantially elevated mRNAs
in early-stage (Ta) UCB. Although the experimental design is
slightly different (see Materials and Methods), both data sets
compare 12–14 normal bladders with 15 Ta UCBs. We used
stringent criteria (2.5-fold change and Po0.001) to select 44 genes
upregulated in both data sets. This list of genes was then compared
with the list of proteins identified by two or more peptides in at
least two of the cell line secretomes (Figure 2). Using this approach,
we arrived at a shortlist of 10 biomarker candidates (Table 2).
Biomarker validation. Two of the candidate biomarkers listed in
Table 2 (midkine and HAI-1) were assessed for their potential as
urinary biomarkers for the detection of UCB. A third protein,
ULBP-2, that was identified in all three secretomes but not
substantially elevated in the microarray data was assayed as a
control. The urine samples were randomly selected from the BCPP
study and approximate to the population presenting with primary
UCB. The distributions of HAI-1, midkine and ULBP-2 in the
control subjects and UCB patients with Ta, T1 and T2þ disease
are shown in Figure 3. Urinary levels of midkine and HAI-1 were
both significantly elevated in patients with UCB relative to control
subjects (Po0.0001). Midkine was significantly elevated in Ta
(P¼ 0.0422, 1.3-fold increase), T1 (Po0.0001, 2.4-fold increase)
and T2þ UCB (Po0.0001, 5.4-fold increase). HAI-1 was
significantly elevated in T1 (Po0.0001, 2.2-fold increase) and
T2þ UCB (Po0.0001, 4.0-fold increase) but not Ta UCB
(P¼ 0.0890). The urinary concentration of ULBP-2 was not
significantly influenced by the presence of Ta, T1 or T2þ UCB
Table 1. Patient Information
Stage n Male/female Grade (1/2/3) Age (years) Creatinine (lgml1) HAI-1 (pgml1) MDK (ngml1)
Control 80 64/16 — 73 (64.8–79.0) 1613 (1054–2457) 533 (195–1085) 3.9 (2.40–10.90)
Ta 287 220/67 123/126/38 73 (63.5–80) 1709 (1082–2373) 538 (299–1344) 5 (2.4–10.9)
T1 149 127/22 2/41/106 74 (66–80) 1742 (1154–2135) 915 (517–2799) 6.5 (3.75–26.2)
T2þ 126 97/29 0/7/119 77 (70–83) 1506 (1025–2153) 2175 (1073–3937) 23.3 (8.18–46.9)
The table shows the number of patients in each group and numbers of males, females and each grade of UCB. All other values are presented as medians (lower quartile—upper quartile).
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Figure 1. Classification of the proteins identified in the conditioned
medium of UCB cell lines. The proteins identified in the conditioned
media and in the corresponding cells were divided into categories
using the GO Cellular Components function in STRING 9.0
(www.string-db.org). The number of proteins in each analysis was:
5637¼ 622/546, EJ28¼ 649/717, HB-CLS-2¼ 822/462 (cell pellet/
secretome).
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(P40.05). We also analysed the data with regard to grade of
disease: HAI-1 and midkine are both most markedly elevated in
higher-grade disease (Figure 4). Midkine was significantly elevated
in G2 (P¼ 0.0017, 1.5-fold increase) and G3 (Po0.0001, 3.9-fold
increase) but not G1 UCB (P¼ 0.5398). Similarly, HAI-1 was
significantly elevated in G2 (P¼ 0.0006, 1.4-fold increase) and G3
UCB (Po0.0001, 3.0-fold increase) but not G1 UCB (P¼ 0.5220).
Neither HAI-1 nor midkine were significantly affected by age or
gender and both have potential as markers for the detection of
UCB as shown by the ROC plots in Figure 5. Areas under the ROC
curves for discrimination between Ta, T1 and T2þ UCB and non-
UCB using midkine were 0.574 (0.522–0.625 95% CI), 0.708
(0.644–0.766) and 0.851 (0.795–0.897), using HAI-1 the areas were
0.566 (0.514–0.618), 0.748 (0.687–0.803) and 0.886 (0.834–0.926).
At 90% specificity, the sensitivities for discriminating between Ta,
T1 and T2þ UCB and non-UCB were 18.1% (13.8–23.1%), 42.3%
(34.2–50.6) and 66.7% (57.7–74.8) using midkine and 16.7% (12.6–
21.6), 47.0 (38.8–55.3) and 74.6% (66.1–81.9) using HAI-1. The
urinary levels of both proteins increase with stage such that, in this
cohort of patients with UCB-like lesions at cystoscopy, midkine
and HAI-1 can discriminate between the presence and absence of
muscle-invasive UCB with areas under the ROC curve of 0.763
(0.728–0.796) and 0.791 (0.758–822), respectively. These data
could be used to stratify patients as to their risk of muscle-invasive
UCB: one third of the patients in this study have an urinary HAI-1
concentration greater than 0.9 pg mg 1 creatinine and a 42% risk
of having muscle-invasive UCB, whereas the two thirds of
patients with HAI-1 below this threshold have an 8% risk
of muscle-invasive UCB.
Serum midkine and HAI-1 and effects of haematuria on
urinary MDK and HAI-1. A major cause of false-positive
results with urinary biomarkers for UCB is haematuria. To address
this we have stratified urinary MDK and HAI-1 levels according to
the level of haematuria determined by dipstick testing (Table 3).
Both proteins show an UCB associated increase in concentration in
urine even in the absence of haematuria. Insufficient haematuric
controls were available to draw reliable conclusions about the effect
of haematuria in the absence of UC (Supplementary Figure 1).
Within each stage of UCB there is a significant increase in urinary
midkine and HAI-1 concentrations with increasing haematuria.
However, urinary midkine and HAI-1 correlate poorly with each
other (r2¼ 0.29) and very poorly with urinary albumin (r2¼ 0.17
in both cases) compared with the correlation between urinary total
protein and albumin concentrations (r2¼ 0.85), suggesting that
haematuria does not directly cause the increased urinary midkine
and HAI-1 concentrations observed in UCB. To further investigate
whether haematuria per se could be responsible for elevated
urinary midkine and HAI-1 we measured both proteins in serum
from 30 non-cancer controls and 50 UCB patients with elevated
urinary midkine and/or HAI-1 (25 NMIBC and 25 MIBC). The
median serum concentrations of midkine were 3.1 and 3.2 ngml 1
for this subset of control and cancer patients, respectively,
compared with median urine concentrations of 3.1 and
54.4 ngml 1 in the same patients. What is more, in all 50 cancer
patients the urine concentration of midkine was higher than the
serum concentration. Median serum concentrations of HAI-1 were
2580 and 2126 pgml 1 for this subset of control and cancer
patients compared with median urine concentrations of 666 and
2759 pgml 1. In 23 of the 50 cancer patients their serum HAI-1
concentration was higher than their urine concentration although a
45-fold ratio was only seen in eight patients and in these cases
urinary HAI-1 was low (median 740 pgml 1). We estimate that
even in the most haematuric sampleso10% of the urine volume is
comprised of plasma (based on albumin concentrations) and that,
196
6
424
Secretomes
44
10
34
121
GSE3167 GSE7476
Figure 2. Identification of candidate biomarkers by combining
microarray and secretome data. The three data sets shown are the
genes upregulated at the RNA level in Ta UCB (GSE3167 and
GSE7476) and proteins identified by two or more peptides in two or
more secretomes.
Table 2. Proteins secreted by UCB cell lines and upregulated in microarray experiments
Gene
symbol
Protein name
GSE3167 fold
change
GSE7476 fold
change
Predicted cellular
location
EJ 5637
HB-
CLS-2
KRT7 Keratin 7 15.7 5.9 Cytoskeleton 0 9 11
MDK Midkine 3.2 4.4 Secreted 10 5 1
KRT19 Keratin 19 5.1 2.6 Cytoskeleton 0 13 12
FABP5 Fatty-acid binding protein 5 4.1 2.6 Cytoplasm 5 5 0
SPINT1 Hepatocyte growth factor activator inhibitor type
1 (HAI-1)
3.8 2.6 Secreted 0 5 10
ADAM10 A Disintegrin and metalloproteinase domain-
containing protein 10
3.0 4.8 Memb/shed 4 0 3
CDH1 E-cadherin 3.2 3.4 Membrane 0 4 8
ENO1 a-Enolase 4.7 2.8 Cyto/memb 28 30 25
KRT8 Keratin 8 2.5 2.6 Cytoskeleton 12 15 15
MARCKS MARCKS 2.7 5.9 Cyto/memb 0 7 3
The fold change is shown for two publicly available microarray data sets along with the predicted cellular location and the number of peptides identified in each secretome.
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therefore, it is very unlikely that haematuria directly causes
elevated urinary midkine in UCB patients or that haematuria
directly accounts for more than a small component of the elevated
urinary HAI-1 seen in UCB patients (Supplementary Figure 2).
Increased release of HAI-1 and midkine and causation of blood/
plasma leakage into the urine may be shared characteristics of
some, but not all, bladder tumours.
DISCUSSION
We have used a combination of proteomics (identification of
proteins secreted by UCB cell lines) and transcriptomics (publicly
available microarray data) to identify candidate biomarkers for
UCB. The tissue transcriptome has advantages over the tissue
proteome for this purpose because a greater proportion of the
genome is typically covered, and upregulated secreted proteins may
have elevated mRNA levels but not accumulate as proteins in the
tissue. Furthermore, there are many microarray data sets in the
public domain that are suitable for the purpose outlined here
(www.ncbi.nlm.nih.gov/geo). Two of the proteins identified using
this method, HAI-1 and midkine, were selected for further analysis
on the basis that their cellular localisation is ‘secreted’ (www.
uniprot.org). Both showed a substantial elevation in the urine of
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Figure 3. Urinary levels of candidate biomarkers in UCB patients:
correlation with stage. Panels A, B and C show levels of midkine,
HAI-1 and ULBP-2 respectively in non-UCB controls and patients with
stage Ta, T1 or T2þ UCB. Data are normalised to urinary creatinine
(units¼pgmg 1 creatinine).
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Figure 4. Urinary levels of candidate biomarkers in UCB patients:
correlation with grade. Panels A, B and C show urinary levels of
midkine, HAI-1 and ULBP-2 respectively in non-cancer controls and
patients with grade 1, 2 or 3 UCB. Data are normalised to urinary
creatinine (units¼pgmg1 creatinine).
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UCB patients, although not in the urine of those with early-stage
low-grade tumours. Other proteins on the shortlist have already
shown potential as urinary biomarkers for UCB. E-cadherin has
previously been measured in a large cohort of UCB patients and
generated an ROC area of 0.72 (Shariat et al, 2005). Cytokeratin 19
(also known as CYFRA 21-1) is elevated in the urine of UCB
patients (Senga et al, 1996). Cytokeratin 8 is measured in
conjunction with cytokeratin 18 by the UBC test, which shows
elevation in the urine of UCB patients (Sa´nchez-Carbayo et al,
1999). Thus, at least 5 of the 10 candidate biomarkers on our
shortlist are elevated in the urine of UCB patients.
HAI-1 inhibits the proteases hepatocyte growth factor activator
and matripase and is a membrane-associated protein that can be
shed into the extracellular milieu (Kataoka et al, 2000). HAI-1 may
have a role in the progression of many cancers (Parr and Jiang,
2006) and has been suggested as a serum marker for prostate
cancer (Nagakawa et al, 2006). Expression of HAI-1 is inversely
related to invasion and metastasis (Parr and Jiang, 2001), and low
expression is considered to be an indicator of poor prognosis in
some cancers (Nakamura et al, 2009). Midkine is an angiogenic
growth factor normally expressed in the foetus but also re-
expressed in many types of cancer (Muramaki et al, 2003). Midkine
mRNA has been reported to be upregulated in UCB tissue and
associated with late-stage disease and poor prognosis (O’Brien
et al, 1996). The two microarray data sets used in this study,
however, both show elevated midkine RNA in Ta UCB, which is
maintained through the later stages. Ikematsu et al (2003) showed
that urinary levels of midkine are elevated in several different
malignant conditions. Ikematsu’s study found that midkine was
elevated in 13 out of 15 UCB patients. Although UCB stage was not
reported by the group, the data are consistent with our data for
muscle-invasive disease. Although Ikematsu’s data support our
findings, our data are the first large-scale assessment of midkine as
a urinary marker for UCB.
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Figure 5. Receiver operating characteristic analysis of Midkine and HAI-1 for the detection of UCB. Both proteins have been normalised to
urinary creatinine. Curves are shown for Ta UCB (solid line), T1 UCB (dashed line) and T2þ UCB (dotted line) vs non-UCB.
Table 3. Effects of UCB and haematuria on urinary HAI-1 and midkine levels. (A) Urine HAI-1 stratified according to haematuria and disease stage. (B)
Urine midkine stratified according to haematuria and disease stage. (C) Number of patients in each group
Blood? Non Ta T1 T2þ
(A)
 0.28 (0.11–0.44) 0.33 (0.16–0.57) 0.56 (0.32–1.17)* 0.97 (0.69–1.64)*
 /þ — 0.61 (0.20–0.839)* 0.46 (0.31–1.03)* 0.81 (0.69–2.12)*
þ — 0.49 (0.17–1.00)* 0.64 (0.29–1.51)* 1.35 (0.65–2.03)*
þ þ — 0.50 (0.29–1.13)* 1.47 (0.65–2.45)* 1.47 (0.85–2.53)*
þ þ þ — 0.82 (0.54–1.14)* 1.17 (0.70–2.34)* 1.50 (1.09–2.50)*
(B)
 2.03 (1.05–4.34) 2.42 (1.18–5.37) 2.78 (1.33–7.62) 5.04 (2.51–15.97)*
 /þ — 4.93 (2.25–9.11)* 4.67 (2.57–11.30)* 11.0 (4.08–21.70)*
þ — 6.28 (3.07–15.7)* 13.00 (4.72–43.90)* 10.20 (4.82–29.0)*
þ þ — 5.72 (2.01–15.20)* 12.80 (7.60–27.30)* 16.60 (12.20–26.80)*
þ þ þ — 8.18 (3.82–16.60)* 10.20 (5.63–35.30)* 20.50 (11.80–38.90)*
(C)
 67 202 63 30
 /þ 4 22 24 10
þ 3 17 14 18
þ þ 3 23 23 31
þ þ þ 3 23 25 37
Patient samples are stratified according to haematuria dipstick test results and are shown normalised relative to creatinine (units¼pg mg 1 creatinine). Values are presented as medians (lower
quartile—upper quartile). Data are not shown for patient groups with no5. All values marked with an asterisk are significantly higher than the non-cancer control group (Po0.05).
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In the two microarray data sets that we have re-analysed both
HAI-1 and midkine mRNA expression is elevated in Ta UCB but
does not increase further with increasing stage (Supplementary
Figure 3). However, the urinary concentrations of both proteins
show clear correlation with stage and grade. It is not clear why the
urinary protein levels and mRNA do not correlate across disease
stages: there is not a strong correlation between the protein levels
and tumour size (data not shown) so it may reflect an increase in
the rate of protein synthesis or secretion in more aggressive
tumours. Regardless of mechanism, the marked increase in HAI-1
and midkine in T2þ UCB indicates potential utility as biomarkers
for muscle-invasive disease. Although one of the key objectives of
bladder cancer research may be the discovery of accurate and
reliable biomarkers for diagnosing UCB and reducing reliance
upon cystoscopy for surveillance, no such biomarkers have been
discovered. It is likely that a multiple biomarker assay will need to
be developed to satisfactorily address these objectives, to which
HAI-1 and midkine may contribute. In-depth proteomic analysis
of secretomes and cell surface proteomes of more UCB cell lines,
comparison with transcriptomic data and validation of more
candidates in clinical samples should further contribute to the
development of a useful urine test for UCB. However, protein
biomarkers for detecting muscle-invasive disease have immediate
clinical utility in a number of settings, either alongside cystoscopic
surveillance or in the intervals between cystoscopic surveillance.
Firstly, for monitoring patients with high-grade T1 tumours who
are being treated with intravesical therapy (usually BCG) (Babjuk
et al, 2011) to guide clinicians on the need for closer monitoring or
more aggressive treatment (for example, radical cystectomy).
Similarly, for monitoring patients who have been treated with
radiotherapy (or chemoradiotherapy) (James et al, 2012) for
muscle-invasive disease. However, we feel that the greatest utility
for these biomarkers could lie with the ‘stratified investigation’ of
patients suspected of having bladder cancer in order to streamline
their diagnosis and staging, and hence speed up their definitive
treatment: instead of the usual series of investigations for
haematuria (urine cytology, upper tract imaging, flexible cysto-
scopy) followed by TURBT and then staging CT scanning for
patients with muscle-invasive disease, those patients with positive
biomarkers at the outset could be ‘fast-tracked’ to immediate
CT scanning that would both image their upper urinary tracts and
stage the disease before TURBT (which has a disruptive effect on
local staging (Salo et al, 1985)). Patients could thus skip one of
the processes in the diagnostic pathway and, hence, proceed to
definitive treatment more rapidly with the added benefit of more
accurate local staging.
ULBP-2 was detected in all three secretomes but was not
upregulated in the UCB microarray data. ULBP-2 is a membrane
bound ligand for the NKG2D receptor and is widely expressed in
tumours but not normal tissues (Onda et al, 2001) and shed by
proteases (Waldhauer and Steinle, 2006). A recent study found
serum ULBP-2 to perform at least as well as CA19-9 for detecting
pancreatic cancer (Chang et al, 2011). In contrast to HAI-1 and
midkine, we did not observe a significant increase in urinary
ULBP-2 in patients with UCB. This is consistent with the notion
that upregulation in transcriptome data is a useful way to select
candidate biomarkers from secretome data, and also that the
increased levels of midkine and HAI-1 in the urine of UCB patients
do not arise from a non-specific leakage of cellular proteins from
the tumour. In addition, plasma levels of HAI-1 and midkine are
not high enough for tumour associated haematuria to account for
the elevated urinary levels of these proteins and the two proteins
are increased to different extents in different samples and do not
correlate well with haematuria (data not shown).
In conclusion, proteins that are both identified in UCB cell line
secretomes and upregulated at the mRNA level in UCB may be
useful as urinary biomarkers for UCB as exemplified by the
elevation of both midkine and HAI-1 in the urine of UCB patients.
This method avoids the difficulties of in-depth proteomic analysis
of body fluids and the lack of suitable comparator cell lines to select
cancer-specific markers from cancer cell line secretomes. This
approach has now proven useful in several types of tumour and
may be of widespread applicability in the cancer biomarker field.
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